DPHARM is the conference that challenges and reports on innovation to shake up the way we do clinical trials to reduce patient/physician burden and drive greater efficiencies. We challenge how we want clinical trials to look by 2030 and share examples from those who are doing something about it. We highlight major opportunities to fundamentally change how clinical trials are operationalized going forward.
The spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive ataxia disorders. SCA Global is a worldwide initiative for clinical research in SCAs and provides a flexible and open research platform to pursue the following goals: 1. To better understand the manifestation, evolution and impact of the various SCAs, 2. To develop and validate biomarkers which can be used in future interventional trials, 3. To facilitate access to people with SCAs who are willing to participate in clinical trials.
The Huntington Study Group’s renowned annual event, HSG 2020: HD in Focus: Navigating HD, will bring together more than 600 of the world’s leading Huntington disease (HD) researchers, health care providers, industry representatives, and members of the HD community to provide a forum for training and education in Huntington disease (HD) and for presentation of new research findings and treatments to the worldwide community.
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2019 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. We also discovered new promising treatments and we learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2020 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage. CTAD 2020 will highlight the latest on trying to get these trials off the ground.